Antiviral treatment for cirrhosis due to hepatitis C: a review.
- Author:
Aravindh SOMASUNDARAM
1
;
Jayanthi VENKATARAMAN
Author Information
1. Department of Gastroenterology and Hepatology, Stanley Medical College and Hospital, Chennai 600001, India. aravindhsom@gmail.com
- Publication Type:Journal Article
- MeSH:
Antiviral Agents;
therapeutic use;
Carcinoma, Hepatocellular;
prevention & control;
virology;
Disease Progression;
Hepacivirus;
Hepatitis C, Chronic;
complications;
drug therapy;
Humans;
Liver Cirrhosis;
drug therapy;
virology;
Liver Neoplasms;
prevention & control;
virology;
Liver Transplantation;
Secondary Prevention
- From:Singapore medical journal
2012;53(4):231-235
- CountrySingapore
- Language:English
-
Abstract:
Chronic hepatitis C infection is an important cause of cirrhosis and hepatocellular carcinoma (HCC). Antiviral therapy (AVT) for patients with cirrhosis due to hepatitis C may retard the progression of cirrhosis and prevent both the development of HCC as well as the recurrence of hepatitis C following liver transplantation. This review highlights the issues associated with AVT for patients with compensated and decompensated cirrhosis due to hepatitis C virus.
